Search Results - "Stein, Jenna"

Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma by Eavarone, David A, Al-Alem, Linah, Lugovskoy, Alexey, Prendergast, Jillian M, Nazer, Rawan I, Stein, Jenna N, Dransfield, Daniel T, Behrens, Jeff, Rueda, Bo R

“…The expression of Sialyl-Tn (STn) in tumors is associated with metastatic disease, poor prognosis, and reduced overall survival. STn is expressed on ovarian…”
Get full text

Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau by Starbuck, Kristen, Al-Alem, Linah, Eavarone, David A, Hernandez, Silvia Fatima, Bellio, Chiara, Prendergast, Jillian M, Stein, Jenna, Dransfield, Daniel T, Zarrella, Bianca, Growdon, Whitfield B, Behrens, Jeff, Foster, Rosemary, Rueda, Bo R

“…Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic…”
Get full text

Abstract 3640: Novel humanized anti-Sialyl-Tn, anti-CD3 bispecific antibodies demonstrate tumor and T-cell specificity for immune activation at the tumor site by Eavarone, David A., Prendergast, Jillian, Rao, Patricia E., Stein, Jenna, Behrens, Jeff, Dransfield, Daniel T.

“…Tumor-associated carbohydrate antigens (TACAs) historically have been challenging targets for antibody therapeutics. Sialyl-Tn (STn) is a cancer specific…”
Get full text

Abstract B28: Targeting the tumor-associated carbohydrate antigen STn with humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibits ovarian cancer tumor growth in vitro and in vivo by Dransfield, Daniel T., Prendergast, Jillian M., Eavarone, David A., Nazer, Rawan, Al-Alem, Linah, Stein, Jenna, Behrens, Jeff, Rueda, Bo

“…Ovarian cancer is the leading cause of death from gynecologic malignancies in the U.S. The current standard of care is tumor debulking followed by…”
Get full text

Abstract B114: Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo by Dransfield, Daniel, Prendergast, Jillian M., Eavarone, David A., Nazer, Rawan, Al-Alem, Linah, Rueda, Bo, Stein, Jenna, Behrens, Jeff

“…Targeted therapeutics that can differentiate between normal and malignant tumor cells represent the ideal standard for the development of a successful…”
Get full text

Abstract 5625: Myeloid derived suppressor cells (MDSCs) express Sialyl Tn (STn) and are a therapeutic target for anti-STn antibody drug conjugates by Eavarone, David A., Rao, Patricia E., Prendergast, Jillian M., Curtis, Adam D., Zhang, Rong, Shopland, Lindsay S., Stein, Jenna N., Behrens, Jeff, Dransfield, Daniel T.

“…Introduction: Myeloid derived suppressor cells (MDSCs) are functionally defined by their capacity to suppress T cell immunity; therefore inhibiting these cells…”
Get full text

Abstract 36: Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificity in vitro and in vivo antitumor efficacy by Prendergast, Jillian M., Eavarone, David A., Rao, Patricia E., Curtis, Adam D., Shopland, Lindsay S., Hoffert, Todd A., Stein, Jenna, Behrens, Jeff, Dransfield, Daniel T.

“…Tumor-associated carbohydrate antigens (TACAs) historically have been challenging targets for antibody therapeutics. Sialyl-Tn (STn) is a cancer specific…”
Get full text